Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...2728293031323334353637...170171»
  • ||||||||||  rivaroxaban / Generic mfg., sirolimus / Generic mfg.
    Journal:  Novel treatment of recurrent orbital venolymphatic malformation with sirolimus and rivaroxaban. (Pubmed Central) -  Nov 15, 2022   
    To this end, a combination of sirolimus, an mTOR inhibitor, and rivaroxaban, a factor Xa inhibitor, were used to reduce the size of the lesion and minimize the risk of thromboembolic events. This treatment has successfully kept the patient's symptoms in remission for greater than 2 years.
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg.
    Journal:  Inherited antithrombin deficiency caused by a mutation in the SERPINC1 gene: A case report. (Pubmed Central) -  Nov 15, 2022   
    Evidence is too limited to assess whether this risk extends to patients on direct oral anticoagulants, and further studies are needed. By this report we highlight that gene detection and phenotypic analysis are important means to study inherited ATD.
  • ||||||||||  Xarelto (rivaroxaban) / J&J, aspirin / Generic mfg., warfarin / Generic mfg.
    Trial completion date, Trial primary completion date, HEOR:  PEPPER: Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement (clinicaltrials.gov) -  Nov 14, 2022   
    P4,  N=20000, Recruiting, 
    Increased costs of DOACs need to be assessed. Trial completion date: Feb 2023 --> Jul 2024 | Trial primary completion date: Aug 2022 --> Jul 2023
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg.
    A Case for Early Transesophageal Echocardiography in Native Mitral Valve Thrombus in a Pediatric Patient (Anaheim Convention Center, Hall A, Board # 137) -  Nov 10, 2022 - Abstract #AAPNCE2022AAP_NCE_2332;    
    Earlier diagnosis in our patient may have prevented further organ damage. We acknowledge that TEE-first approach would not be appropriate in all patients but encourage pursuits of more clearcut guidelines for children and adolescents, especially ones considering patient age and size.
  • ||||||||||  Pulmonary Embolism in Pediatric Patients with Recent COVID-19 Infection: A Case Series (Anaheim Convention Center, Hall A, Board # 188) -  Nov 10, 2022 - Abstract #AAPNCE2022AAP_NCE_2281;    
    He was discharged after 24 hours, continued enoxaparin for 5 days, and then transitioned to oral dabigatran for three months with hematology follow-up...The patient was treated initially with heparin and then with enoxaparin, remdesivir, albuterol, azithromycin, and IV solumedrol...He was started on heparin, transitioned to enoxaparin therapy, and subsequently oral rivaroxaban due to insurance coverage... These three cases emphasize that pediatric patients with identifiable prothrombotic risk factors are at risk for developing serious complications secondary to COVID-19 infection, and as such, increased suspicion for VTE development should be present in these situations.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Retrospective data, Journal, Real-world evidence:  Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data. (Pubmed Central) -  Nov 10, 2022   
    However, high ischemic cerebrovascular event and low nonmajor bleeding rates are remarkable in low dose use of rivaroxaban. It is clear that there is a need to consider existing dose reduction criteria in terms of correct prescribing.
  • ||||||||||  rivaroxaban / Generic mfg.
    DEVELOPMENTAL VENOUS ANOMALY PRESENTING AS AN ACUTE STROKE MIMIC: IS THROMBOLYSIS JUSTIFIED? (GALLERY) -  Nov 7, 2022 - Abstract #WSC2022WSC_1500;    
    Developmental venous anomaly should be considered in the differential diagnosis of acute ischemic stroke. CT brain demonstrating vascular channels inconsistent with normal arterial pattern or hemispheric hypodensity not confined to a vascular territory should be interrogated with additional imaging before thrombolysis.
  • ||||||||||  CHALLENGES IN CEREBRAL THROMBOSIS (GALLERY) -  Nov 7, 2022 - Abstract #WSC2022WSC_1346;    
    The most appropriate, pharmacological attempt for our patients would have been apixaban. Further studies are needed in order to validate efficacy and safety of NOACs in CVT, the duration of prescription, especially if genetic polymorphisms linked to CVT are identified.
  • ||||||||||  rivaroxaban / Generic mfg.
    EMBOLIC STROKE AS FIRST PRESENTATION OF GALLBLADDER CANCER (GALLERY) -  Nov 7, 2022 - Abstract #WSC2022WSC_1312;    
    Comprehensive young stroke work up including malignancy screening should be considered. The optimal antithrombotic treatment strategy for cancer-related ESUS remains uncertain, especially because of the high risk of bleeding in these patients.
  • ||||||||||  Noxafil (posaconazole) / Merck (MSD)
    INTRACEREBRAL HEMORRHAGE CAUSED BY MUCORMYCOSIS IN A PATIENT WITH A HISTORY COVID 19 ILLNESS (GALLERY) -  Nov 7, 2022 - Abstract #WSC2022WSC_1069;    
    Mucormycosis is an aggressive, disseminated disease associated with vascular invasion and thrombosis, particularly in patients with history of COVID -19 illness. Early recognition and treatment are critical in order to improve clinical outcomes and decrease the development of complications.
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
    Real-World Experience of Direct Oral Anticoagulant Use in a Single Pediatric Center (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_3933;    
    The bleeding and recurrent VTE rates after DOACs appear comparable to other anticoagulants in pediatric VTE; heavy menstrual bleeding should be investigated in adolescent females. Given the recent approval of DOACs for pediatric patients, additional multi-centered outcome studies are needed to determine recurrence and bleeding risks.
  • ||||||||||  Intermediate Results of the Cornell Blood Coagulation in Cancer Study (COBLOCA-Study) (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_3917;    
    Seven patients used aspirin in addition to anticoagulants, and 10 patients only used aspirin...Conclusion Both VWF antigen and activity were significantly increased in cancer patients with a history of VTE, indicating that the vessel wall plays an important role in cancer-associated thrombosis. Likewise, elevated D-dimer levels, and reduced levels of available coagulation factors in cancer patients with a history of VTE indicate that these patients might be in a more pro-coagulant state, resulting in (sub-clinical) consumption of coagulation factors and ongoing low grade intra-vascular coagulation.
  • ||||||||||  A Multicenter Study of Safety, Tolerability, and Effectiveness of Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia (ENMCC - 288-290) -  Nov 4, 2022 - Abstract #ASH2022ASH_3623;    
    Discontinuation rates approached 50% regardless of dose-intensity at initiation or type of antithrombotic agent used and were higher in patients with a history of gastrointestinal bleeding. These findings, from the largest and most comprehensive evaluation of antithrombotic therapy in HHT to date, challenge at least two recommendations made based on limited prior data or expert opinion alone in the Second International HHT Guidelines: the recommendation for use of warfarin or heparin-based therapy over DOACs and the avoidance of multiple simultaneous agents even when otherwise indicated due to concern for higher bleeding risk.
  • ||||||||||  apixaban / Generic mfg.
    A Prospective Study of Apixaban for Central Venous Catheter Associated Upper Extremity Deep Vein Thrombosis in Cancer Patients: Catheter 3 (ENMCC - 291-292) -  Nov 4, 2022 - Abstract #ASH2022ASH_3521;    
    UEDVT may be treated with low molecular weight heparin (LMWH) either as monotherapy or subsequently transitioned to warfarin as we have previously shown (Kovacs 2007)...Due to the fact that in the Catheter 2 Study most bleeds occurred while taking 15 mg bid of Rivaroxaban, for this study, patients were treated with dalteparin, 200 IU/kg x 7days followed by Apixaban 5 mg po bid to complete 12 weeks...(1 patient had 2 major bleeds). Discussion In this study, Apixaban showed promise in treating CVC-associated UEDVT in cancer patients, resulting in high preserved CVC function.